ADVISORY, Feb. 12, 2008 (PRIME NEWSWIRE) --
What: Harvey J. Berger M.D., Chairman and Chief Executive Officer of ARIAD Pharmaceuticals (ARIA), will preside over the NASDAQ opening bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday, February 13, 2008 at 9:30 a.m. ET Contacts: Sheryl Seapy 949.608.0841 sheryl@purecommunicationsinc.com NASDAQ MarketSite: Jolene Libretto; 646.441.5220 Jolene.Libretto@nasdaq.com
Feed Information:
The opening bell is available from 9:20 a.m. to 9:35 a.m. on Galaxy 26 - uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About ARIAD Pharmaceuticals, Incorporated (ARIA):
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need -- aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate in late-stage clinical development in a broad range of cancers. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor entering Phase 1 clinical development. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.